The long non-coding RNAs (lncRNAs) are subject of intensive recent studies due to its association with various human diseases. It is desirable to build the artificial intelligence-based models for prediction of diseases or tissues based on the lncRNAs data, which will be useful in disease diagnosis and therapy. The accuracy and robustness of existing models based on the machine learning techniques are subject to further improvement. In this study, we propose a deep learning model, called Multi-Label Classifications with Deep Forest, termed MLCDForest, to address multi-label classification on tissue prediction for a given lncRNA, which can be regarded as an implementation of the deep forest model in multi-label classification. The MLCDForest is a sequential multi-label-grained scanning method, which distinguishes from the standard deep forest model. It is proposed to train in sequential of multi-labels with label correlation considered. A systematic comparison using the lncRNA-disease association datasets demonstrates that our method consistently shows superior performance over the state-of-the-art methods in disease prediction. Considering label correlation in the sequential multi-label-grained scanning, our model provides a powerful tool to make multi-label classification and tissue prediction based on given lncRNAs.
Drug-target interactions play a crucial role in target-based drug discovery and exploitation. Computational prediction of DTIs has become a popular alternative strategy to the experimental methods for identification of DTIs of which are both time and resource consuming. However, the performances of the current DTIs prediction approaches suffer from a problem of low precision and high false positive rate. In this study, we aimed to develop a novel DTIs prediction method, named DTI-CDF, for improving the prediction precision based on a cascade deep forest model which integrates hybrid features, including multiple similarity-based features extracted from the heterogeneous graph, fingerprints of drugs, and evolution information of target protein sequences. In the experiments, we built five replicates of 10 fold cross-validations under three different experimental settings of data sets, namely, corresponding DTIs values of certain drugs ( SD ), targets ( ST ), or drug-target pairs ( SP ) in the training set are missed, but existed in the test set. The experimental results show that our proposed approach DTI-CDF achieved significantly higher performance than the state-of-the-art methods.